Key Highlights
- Arecor Therapeutics PLC (LSE:AREC) shares fell 18.08% on 30 September 2026.
- The company conditionally placed 7,352,941 new shares at 68p to raise about £5.0 million before expenses.
- A separate retail offer aims to raise up to £0.13 million at the same price.
- Proceeds are expected to extend the cash runway to December 2027 and support insulin Partnership negotiations.
Why Arecor Therapeutics (LSE:AREC) Is in Focus
Arecor Therapeutics PLC (LSE:AREC), the Cambridge-based clinical-stage biotech developing therapeutics for diabetes, obesity and cardiometabolic diseases, was among London's notable decliners on 30 September 2026. The shares dropped 18.08% after the company announced and completed an accelerated bookbuild.
Arecor confirmed it had placed 7,352,941 new ordinary shares at 68p each with institutional and professional investors. A retail offer for qualifying existing UK shareholders seeks up to a further £0.13 million, equal to 191,176 shares at the same price.
Key Reasons Behind the 18.08% Share Price Fall
The first reason was dilution. Assuming the retail offer is fully taken up, the new shares will represent around 20% of the existing issued share capital. A one-fifth increase in share count is significant for a company with a Market Value previously in the mid-£20 million range.
The second reason was pricing. The 68p issue price was a 1.9% premium to the 60-day volume-weighted average price of 66.7p, but the shares had recently traded above this level, including the mid-70p range in early September. Markets often pull a stock towards the placing price once terms are confirmed.
How Arecor Plans to Use the Money
Arecor said the net proceeds will strengthen its Balance Sheet during expanded partnership negotiations with multiple insulin pump companies. Management believes a larger cash position improves its negotiating stance with large device partners.
The funds will also support insulin development activities and extend the cash runway to December 2027. The new shares are being issued under authorities granted at the 2026 annual general meeting, so no further Shareholder approval is needed. Admission to trading on AIM is expected at 8:00am on 6 October 2026.
Ultra-Concentrated Insulin Strategy
Arecor's lead focus is ultra-concentrated, rapid-acting insulin designed for use in smaller, longer-wearing insulin pumps and patch pumps. The company recently signed a co-development agreement with Sequel Med Tech to combine its insulin with Sequel's pump technology.
Higher-concentration insulin can allow devices to carry more insulin in a smaller reservoir, which can improve convenience for people with diabetes and support next-generation automated insulin delivery systems. This is why pump makers are a natural partner group for the company.
What Investors Are Watching
The first watch point is partnership announcements. With negotiations underway with several insulin pump companies, a signed deal could validate the platform and bring non-dilutive income.
The second watch point is clinical and regulatory progress for its insulin candidates.
The third watch point is the retail offer outcome and the trading pattern around the 68p placing price after new shares are admitted.
The fourth watch point is cash discipline. The runway to December 2027 gives time, but investors will monitor spending against milestones.
Diabetes Technology Backdrop
The diabetes device market continues to shift towards automated insulin delivery and wearable pumps. Drug formulations that work well in these devices are in demand, giving specialist formulation companies a role in the wider ecosystem.
Outlook
Arecor Therapeutics (LSE:AREC) has secured funding to support its insulin partnering strategy, but shareholders absorbed meaningful dilution in exchange. The share price reaction reflects near-term Supply of new stock rather than a change in the science. Partnership updates and progress with pump developers will be the main catalysts in coming months.






Please wait processing your request...